Skip to main content
. 2014 Nov 3;4:6872. doi: 10.1038/srep06872

Figure 1. Molecular structures of inhibitors, PR1 and PR2.

Figure 1

(A) Darunavir(DRV), (B) superimposed structures of PR1 (violet) and PR2 (cyans) in a cartoon diagram, (C) Amprenavir (APV), (D) superimposed structures of the inhibitor-PR1 (violext) and inhibitor-PR2 (cyans) complexes in a cartoon diagram. DRV, APV and key residues are shown in sticks.